A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer (RAP)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by Duke University
Sponsor:
Collaborators:
Amgen
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Herbert Hurwitz, MD, Duke University
ClinicalTrials.gov Identifier:
NCT01061788
First received: February 2, 2010
Last updated: August 25, 2014
Last verified: August 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: April 2017
  Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)